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Acute inhalation studies are conducted in animals as part of chemical hazard identiﬁcation and char-
acterisation, including for classiﬁcation and labelling purposes. Current accepted methods use death as
an endpoint (OECD TG403 and TG436), whereas the ﬁxed concentration procedure (FCP) (draft OECD
TG433) uses fewer animals and replaces lethality as an endpoint with ‘evident toxicity.’ Evident toxicity
is deﬁned as clear signs of toxicity that predict exposure to the next highest concentration will cause
severe toxicity or death in most animals. A global initiative including 20 organisations, led by the Na-
tional Centre for the Replacement, Reﬁnement and Reduction of Animals in Research (NC3Rs) has shared
data on the clinical signs recorded during acute inhalation studies for 172 substances (primarily dusts or
mists) with the aim of making evident toxicity more objective and transferable between laboratories.
Pairs of studies (5 male or 5 female rats) with at least a two-fold change in concentration were analysed
to determine if there are any signs at the lower dose that could have predicted severe toxicity or death at
the higher concentration. The results show that signs such as body weight loss (>10% pre-dosing weight),
irregular respiration, tremors and hypoactivity, seen at least once in at least one animal after the day of
dosing are highly predictive (positive predictive value > 90%) of severe toxicity or death at the next.
ell).
Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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GHS classiﬁcations for LC50 by inhalation.
GHS category Vapours (mg/L) Dusts and mists (m
1 (most toxic) 0.5 0.05
2 >0.5 and 2 >0.05 and 0.5
3 >2 and 10 >0.5 and 1
4 >10 and 20 >1 and 5
5 (least toxic) >20 >5
GHS, Globally Harmonised System; LC50, median co
million.highest concentration. The working group has used these data to propose changes to TG433 that
incorporate a clear indication of the clinical signs that deﬁne evident toxicity.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
1.1. Background
Acute inhalation studies are conducted in animals as part of
chemical hazard identiﬁcation and characterisation. Current
accepted methods, LC50 (OECD TG403 (OECD, 2009a)) and the
acute toxic class (ATC) (TG436 (OECD, 2009b)) use death as an
endpoint. These are described in more detail below. In an effort to
reduce animal numbers and to improve welfare, an alternative
ﬁxed concentration procedure (FCP) was proposed in 2004 (draft
OECD TG433 (OECD, 2004) which replaced lethality as an endpoint
with ‘evident toxicity.’ This was deﬁned as those signs of toxicity
that predict severe toxicity or death in most animals at the next
highest concentration of the chemical. The FCP was dropped from
the OECD work plan in 2007 because of a lack of evidence for
comparable performance with TG403 and TG436, suspected sex
differences in the level of toxic effects (since the FCP was originally
proposed to use females as the default sex) and the ill-deﬁned and
subjective nature of evident toxicity. The ﬁrst two issues have been
resolved (Price et al., 2011; Stallard et al., 2011) through work
supported by the UK National Centre for the Replacement,
Reﬁnement and Reduction of Animals in Research (NC3Rs) thereby
leaving only the deﬁnition of evident toxicity to be determined. To
this end, the NC3Rs launched a global initiative involving 20 or-
ganisations with the aim of making evident toxicity more objective
and transferable between laboratories. The group shared data on
the clinical signs recorded during acute inhalation studies for 172
substances, the majority of which fell under the category of dusts
and mists (from completed studies held in the archives of partici-
pating laboratories), and determined which signs have high posi-
tive predictive value (PPV) for severe toxicity or death at the next
highest concentration (as described below). The draft OECD TG433
is now back on the OECD work plan, pending the outcome of this
work.
1.2. Acute inhalation studies
The two existing guidelines (TG403 and TG436) are described
here in some detail because the data used for the analysis in this
paper originated from studies run according to these protocols. The
FCP (draft TG433) is the preferable method for investigation of
acute inhalation toxicity for classiﬁcation and labelling purposes
based on animal welfare grounds (preventing unnecessary
suffering by eliminating the need to test at higher actual lethal
doses). This method has been shown to be comparable with both
existing methods in estimating the toxic class to which a substance
belongs (Stallard et al., 2011).g/L) Gases (ppm)
100
>100 and 500
>500 and 2,500
>2,500 and 20,000
>20,000
ncentration; ppm, parts per1.2.1. LC50 method (TG403)
The LC50 of a substance is the concentration that can be ex-
pected to cause death in 50% of the animal population, where
‘death’ is deﬁned as compound-related mortality within 14 days.
The LC50 is used to classify substances (dust andmists, vapours, and
gases) under the Globally Harmonised System of Classiﬁcation and
labelling of chemicals (GHS) (OECD, 2001). The test speciﬁes that 10
animals (5 males and 5 females) should be exposed at each of three
concentration levels. The concentration levels should be sufﬁ-
ciently spaced to enable construction of a mortality curve and an
estimate of the LC50 to be obtained. The LC50 is then used to classify
the toxicity of the chemical, according to Table 1 and as illustrated
in Fig. 1.
1.2.2. Acute toxic class method (TG436)
The acute toxic class (ATC) method (TG436) has been accepted
as an alternative method to the LC50 test (OECD TG403). Whilst the
test uses fewer animals, death is still used as an endpoint. The test
speciﬁes that 6 animals (3 males and 3 females) are tested at ﬁxed
concentrations that form the upper limit of the GHS categories (e.g.
0.05, 0.5, 1 and 5 mg/L for dusts and mists) (Table 1). The starting
concentration is either the highest concentration, or that which is
expected to lead tomortality in some of the exposed animals, based
on prior information. At each concentration decisions are based on
the number of observed deaths from the combined group of ani-
mals. Either a classiﬁcation is made or testing continues at the next
higher or lower concentration, depending on the starting concen-
tration, as shown in Fig. 2.
1.2.3. The ﬁxed concentration procedure (FCP) (TG433)
The FCP test method is similar to the ATC method above but
decisions and classiﬁcations are instead based on evident toxicitye
clear signs of toxicity such that it can be predicted that exposure to
the next highest concentration would cause death in most animals.
The draft FCP protocol starts with a sighting study in which single
female animals are exposed sequentially to one or more concen-
trations. Information from the sighting study can be used to classify
the substance (if there is death at the lowest concentration the
substance is classiﬁed into the most toxic class) or to guide de-
cisions for an appropriate starting concentration of the main study.
Comparison of the FCP test with the existing methods showed that,
in the absence of sex differences, the results are similar (Price et al.,
2011). Since the original FCP design proposed testing in female rats,
the NC3Rs working group suggested the inclusion of a modiﬁed
sighting study to take into account any sex differences in sensitivity.
This involves the testing of one male and one female, to choose the
most sensitive gender to take forward to main study testing. The
main study then uses females (unless males are indicated as the
more sensitive sex), where groups of ﬁve animals are exposed at
each concentration until a decision on classiﬁcation can be made.
As for the ATC, substances are tested at ﬁxed concentrations that
form the upper limit of the GHS categories (e.g. 0.05, 0.5, 1 and
5 mg/l for dusts and mists) (Table 1). At each concentration de-
cisions are based on the number of deaths and/or the number of
animals experiencing evident toxicity, and either a classiﬁcation is
made or testing continues at the next higher or lower concentra-
tion, depending on the starting concentration (Fig. 3).
An issue that needed to be addressed by the group is the
Fig. 1. LC50 test (OECD test guideline 403) for dusts and mists, using example concentrations, starting at 5 mg/L (Price et al., 2010). Please note the LC50 test method does not require
ﬁxed concentrations, but speciﬁes that 10 animals (5 males and 5 females) should be exposed at three different concentration levels. The concentration levels should be sufﬁciently
spaced to enable construction of a mortality curve so that an estimation of the LC50 can be obtained.
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fold within a class of substance (Table 1). The impact of this on the
determination of evident toxicity is discussed below.1.3. NC3Rs FCP working group and objectives
The NC3Rs assembled a working group of individuals from 19
other organisations listed as co-authors of this paper. The organi-
sations include contract research organisations (CROs) and regu-
latory and standards bodies from Europe, US, Korea and Japan. TheFig. 2. Acute toxic class (ATC) method for dusts and mists for an example starting concentrat
males and 3 females) are tested at ﬁxed concentrations that form the upper limit of the GHS
is expected to lead to mortality in some of the exposed animals, based on prior informatioultimate objective of the group is to encourage the adoption of the
FCP as a preferred alternative to existing methods (TG403 and
TG436) for acute inhalation studies. This is to be achieved through
the generation of an evidence base of clinical signs to identify signs
that predict exposure to a higher concentration would result in
severe toxicity or death. The development of objective and vali-
dated assessment criteria for evident toxicity will provide guidance
on the recognition of evident toxicity to inform decisions made
during a study and for classiﬁcation and labelling purposes. The raw
data for the analysis were provided by six of the collaboratingion of 5 mg/L (Price et al., 2010). Please note, the ATC method speciﬁes that 6 animals (3
categories. The starting concentration is either the highest concentration, or that which
n.
Fig. 3. Fixed concentration procedure (FCP) method for dusts and mists for an example
starting concentration of 5 mg/L (Price et al., 2010). Please note, the draft test guideline
speciﬁes that substances are tested at ﬁxed concentrations that form the upper limit of
the GHS categories. The starting concentration is chosen to be the ﬁxed concentration
level that is most likely to lead to evident toxicity but not death.
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clinical signs. The datawere received by the NC3Rs and anonymised
to ensure that data could not be linked back to the originating
organisation or to the chemical being tested.2. Methods
2.1. Clinical signs recording system and data collection
A clinical signs recording system was developed with the
expertise of the working group and piloted at four UK CROs to re-
cord the clinical signs observed in individual animals during acute
inhalation studies. A code was assigned to each clinical signTable 2
Clinical sign lexicon.
General Movement
BW Body weight loss A Ataxia
CTT Cold to touch/hypothermia AG Abnormal gait
EM Thin C Circling movem
DH Dehydration ET Elevated tail
WTT Warm to touch HT Tilted head
Behaviour LL Limited use of l
AGG Aggressive RM RS SR
AR Appetite reduced RR Impaired righti
HS Heightened sensitivity to sound WR Writhing
HST Heightened sensitivity to touch Tremors/convulsions
I Overactive/hyperactive CV Convulsions
L Underactive/hypoactive T Body tremors
MU Self-mutilation TW Twitching/fasci
Q Subdued Posture/muscle tone
V Vocalising H Hunched postu
Appearance IBT Increased body
AD Abdominal discomfort PO Prone/ﬂat postu
CY Cyanosis PR Prostrate
DA Distended abdomen RBT Reduced body t
DF Distended/swelling face Eyes
ES Superﬁcial eschar (scab) B Eye bulging
HL Hair loss/alopecia CP Constricted pup
P Pilo-erection DE Eyes dull
PA Pallor DP Dilated pupil
PP Prolapsed penis EC Eye closed
SKT Skin tenting ED Eye damaged
TB Teeth broken OE Opacity of eye
UG Rough/unkempt coat PtPC Eyes partially c
WF Wet coat SW Eyelids swollenobserved. The trial was extended to collect data on the clinical signs
observed in individual animals during acute inhalation studies
conducted at six international laboratories for classiﬁcation and
labelling purposes. Table 2 lists the clinical signs and codes
included in the clinical signs lexicon.
Data on the clinical signs observed in individual animals in acute
inhalation studies for 172 substances, carried out at two or more
concentrations, were provided by six international laboratories.
These data were from either LC50 or ATC tests, but since the
monitoring procedure is the same as for the FCP (i.e. daily moni-
toring of clinical signs for 14 days) they could be used to evaluate
evident toxicity relevant for the FCP protocol. However, as detailed
below, various exclusion criteria were applied to the data to make
them more relevant to the FCP. Information was also collected on
the type of substance (gas, dust, or vapour), as well as the test
performed (LC50 or ATC), and the outcome of the study (e.g. further
testing or GHS classiﬁcation) (Table 3). Although listing the severity
of each clinical sign was an option in the survey, this was not
recorded systematically, and, with the exception of body weight
loss, for the sake of consistency was not further considered in the
analysis of evident toxicity.2.2. Harmonisation of the dataset
Since archived data were collected from a number of labora-
tories there was some variation in the original terminology and
signs recorded. Consequently a retrospective, harmonised list of
clinical signswas agreed upon by all members of theworking group
for the purposes of analysis, and appropriate re-coding was made
where needed. For example rales (dry) and rales (moist) were
reassigned to code RN (noisy respiration). Varying descriptions of
gait (shufﬂing, splayed, tiptoe) were grouped and assigned code AG
(abnormal gait). Loose faeces and diarrhoea were deemed
equivalent.Respiration
IR Irregular respiration
RD Slow respiration
ent RG Gasping
RI Rapid/fast respiration
RL Laboured respiration/dyspnea
imbs RN Noisy respiration
RS Sneezing
ng reﬂex SR Shallow respiration
Secretion/excretion
DU Diuresis
FAC Faeces abnormal colour
FR Faeces reduced
culation LF Loose faeces/diarrhoea
ND Increased ocularenasal lacrimation
re OD Oral discharge
tone UR Urine abnormal colour
re S Increased salivation
Staining
one FAS Facial staining
FS Generalised fur staining (caused by test item)
SH Stained head
il SF Generalised brown fur staining
UGS Ano-genital staining
Consciousness
CO Unconscious
MO Moribund
O Active & healthy
losed/ptosis XD Found dead
XE Animal euthanized after observations
Table 3
Substance information sheet.
Substance information sheet Please provide additional
information where possible
Inhalation type [Select] Please select
Method of inhalation [Select] Please select
Particle size (mmad) [Enter]
Concentration tested [Enter] Please specify units
Start time of exposure [Enter]
Duration of exposure [Enter]
Species tested [Enter]
Strain tested [Enter]
Chemical class [Enter]
Known toxic effects or mode(s)
of toxicity
[Enter]
Subsequent GHS classiﬁcation
(please select)
[Select] Please select
Outcome of study [Select] Please select
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The data were analysed to determine whether there were any
clinical signs (or combination of signs) observed in animals at a
lower concentration that could predict toxicity at the next or higher
concentration. Although evident toxicity is deﬁned in the guideline
as that which ‘predicts deaths in a majority of animals at the next
higher concentration’, thereby enabling classiﬁcation according to
Outcome B in Fig. 3, toxicity enabling classiﬁcation according to
Outcome A speciﬁes only 2 or more deaths per group of 5, i.e. 40%
or more. In view of this inconsistency, we agreed to deﬁne evident
toxicity as that which predicts ‘toxicity’ at the higher concentration,
itself deﬁned as death, or severe toxicity requiring euthanasia, in
two or more out of ﬁve animals.
Since the dataset included studies that were conducted ac-
cording to both the LC50 and ATC protocols, there was wide varia-
tion in the concentration levels and intervals used. The fold changes
in concentrations for the FCP protocol range from two to ten-fold,
depending on the substance class, while the fold changes in con-
centrations in the data set varied from 1.02 to 20-fold. Therefore in
this analysis tests were restricted to thosewith a two or greater fold
difference in concentration between the lower and the higher
exposure (Fig. S1).
The parameters used to analyse the dataset are the positive
predictive values (PPV), the speciﬁcity, the sensitivity and the false
positive or negative rates where:
▪ PPV is deﬁned as the proportion of times that the presence of
the clinical sign at the lower concentration is predictive of
toxicity at the next highest concentration
▪ Sensitivity is deﬁned as the proportion of ‘toxicities’ (death of
two or more animals) at the higher concentration that are
associated with the clinical sign at the lower concentration
▪ Speciﬁcity is deﬁned as the proportion of non-toxicity that is
associated with the absence of the clinical sign at the lower
concentration
▪ The false positive rate is the proportion of times that the pres-
ence of the clinical sign at the lower concentration does not
predict toxicity at the next highest concentration (therefore 1-
PPV)
▪ The false negative rate is the proportion of the times that the
absence of the clinical sign at the lower concentration is asso-
ciated with toxicity at the next highest concentration
In the context of the FCP test, high values of PPV are required to
avoid false positives that would lead to a more severe (butincorrect) GHS classiﬁcation. Admittedly this would err on the side
of caution for human safety and 3Rs considerations, but would not
be attractive from the business perspective. Sensitivity is less
important because there is no expectation that a single sign would
sufﬁce to predict all higher concentration toxicities. In a purely 3Rs
context, any sign with very high PPV is attractive regardless of the
sensitivity, but very low levels of sensitivity are less useful in
practice because of their rare occurrence and small contribution to
determining evident toxicity. Lower sensitivity is related to a higher
proportion of false negatives i.e. toxicity at the higher concentration
not predicted because the sign was absent at the lower concen-
tration. Since this absence would naturally lead to further testing at
the higher concentration, false negatives do not compromise the
assessment of hazard, but are unsatisfactory from the 3Rs
perspective.
In order to relate the analysis to the draft FCP protocol, various
inclusion criteria and deﬁnitions were applied to the data. Com-
parisons of data from a lower and higher concentration were
restricted to:
▪ a single sex, either male or female (FCP proposes testing of fe-
males only unless males are indicated as the most sensitive sex
in the sighting study)
▪ a difference in concentration of at least two-fold (as described
earlier to reﬂect the minimum concentration change in the
protocol, Table 1)
▪ studies that had 5 animals per sex per group (the FCP tests 5
males or females)
▪ signs that were observed on days other than day 0 (the day of
dosing) so that signs could be deﬁnitively related to the test
substance rather than the inhalation or restraint procedure and
so that predictions were based on signs that persisted/appeared
24 h after exposure (considered in more detail below)
▪ signs observed up to 14 days after dosing (the FCP requires daily
monitoring for 14 days after exposure)
As in the draft FCP protocol, toxicity at the higher concentration
is deﬁned as severe toxicity requiring euthanasia or death in at least
two out of the ﬁve animals. Therefore data for animals found dead
(XD) or euthanised after observation (XE) were combined or used
interchangeably.
The impact on the results of not including these restrictions was
considered and is referred to in the results section that follows.
2.4. Statistical analysis
The ability of signs at the lower concentration to predict toxicity
at the higher concentration was determined by examining 2  2
tables of whether one or more lower concentration animals
showed a sign (or combination of signs) and whether 2 or more
higher concentration animals died or were euthanized, and calcu-
lating the proportion of correct predictions. Conﬁdence intervals
were obtained from themid-P conﬁdence interval adaptation of the
Clopper-Pearson interval (Agresti and Gottard, 2005). Differences
between prevalence of signs in male and female animals was tested
by ﬁtting generalised linear models for the number of animals out
of 5 showing a sign, with terms for test and sex.
3. Results
3.1. Properties of the original dataset
The original data set of tests on 188 substances included 511
pairs of studies on 4638 animals. These included information from
a variety of procedures (LC50 and ATC) and concentrations tested,
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ried out in rat (typically 5 males and 5 females, although there
were a small number of studies with fewer or greater numbers of
animals per group) and animals were usually exposed to the
inhalation substance for 4 h and then monitored daily for 14 days.
In studies conducted for a longer period (21 or 28 days), only the
data from the ﬁrst 14 days was included in the analysis. Studies
that used fewer than 5 males or 5 females were excluded from
further analysis, as were data within studies in which the fold-
change in exposure from one concentration to the next higher
was less than two. Most of the remaining studies used both males
and females although a number were conducted only in a single
sex. All of these were considered eligible and in the rest of this
paper, we use the term “study” to indicate a set of data from either
5 males or 5 females at two concentrations differing by at least a
factor of 2. There were 427 pairs of these studies, from 172 sub-
stances, involving 3695 animals. The majority of these substances
fall under the category of dusts and mists (165 substances), with a
small number of gases (5 substances) and vapours (2 substances).
However, since the purpose of the exercise is to look at the clinical
signs observed and link these to the prediction of death or severe
toxicity at a higher dose, the class of compound is largely
irrelevant.3.2. Death as a predictor of toxicity at the next highest
concentration
A large proportion of animals were found dead during the
studies and some required euthanasia. There were only 44 studies
in which there were no deaths or euthanasia at either concentra-
tion, 1 in which one or more deaths were found only at the lower
concentration, 224 in which death was found only at the higher
concentration and 158 in which death was found at both
concentrations.
‘Toxicity’ was deﬁned as the death of two or more animals at the
higher concentration. The presence of two deaths per ﬁve animals
at the lower concentration was not surprisingly strongly associated
with toxicity at the next higher exposurewith a PPV of 98%. On rare
occasions, death was more frequent at the lower concentration for
unknown reasons.
One death only (1/5 animals) recorded at the lower exposure
was also highly predictive of toxicity at the higher concentration
(PPV 93%, 95% CI 84e98%). A subset of studies (28withmale rats, 29
with females) was used to investigate whether the presence of
additional signs in a group of animals in which one death had been
recorded at the lower concentration could increase the PPV. Table 4
shows that a small number of additional signs observed at least
once in one animal increased the PPV to 100% with varying degrees
of sensitivity. Most of these had high predictive value in the
absence of death as described later.Table 4
A list of a small number of additional clinical signs, that if observed in the remaining ani
death of one animal at the lower dose has a PPV of 93%.
Clinical sign Code PPV (95% CI) Sensitivity (9
Irregular respiration IR 100.0 (90.2e100.0) 54.7 (4
Abnormal gait AG 100.0 (76.2e100.0) 20.8 (1
Slow respiration RD 100.0 (71.7e100.0) 17.0 (8
Tremors T 100.0 (65.2e100.0) 13.2 (6
Oral discharge OD 100.0 (60.7e100.0) 11.3 (4
Hypoactivity L 94.7 (83.7e99.1) 67.9 (5
Bodyweight loss BW 93.3 (79.7e98.9) 52.8 (3
Hunched posture H 93.1 (79.1e98.8) 50.9 (3Finally, even when no deaths were recorded at the lower
exposure, toxicity at the higher concentration occurred in 77% (95%
CI 72e82%) of studies.
3.3. Signs observed on day 0
Signs observed onday 0mayhave resulted from the restraint and/
or inhalation procedure rather than the chemical itself. In fact some
signs were only (e.g. wet coat, writhing) or mainly (e.g. bulging eyes,
eyes closed, overactive) observed on day 0 lending weight to this
argument. However, some of the most common and severe signs
were seen on day 0 as well as on other days, and an analysis was
carried out to see the effect of inclusion and exclusion of these signs.
On the whole, inclusion of day 0 observations decreased the pre-
dictivity of the sign. In other words, signs that persisted 24 h after
exposure improved the predictivity. A good example is hypoactivity
(L),whichwasmuchmore frequentlyobservedonday0 thanonother
days. However, as a predictor of toxicity, inclusion of the day 0 inci-
dence decreased predictivity from 100% to 92% and speciﬁcity from
100% to88% (seeTable5).Other signs suchas irregular respiration (IR)
were similarly affected but to a lesser extent (Table 5). The decreases
in predictivity and speciﬁcity were adopted as the justiﬁcation for
excludingday0observations fromouranalyses.However, it shouldbe
noted that if severe signs are seen on day 0, the usual procedures
should be followed to stop a study or euthanize as appropriate.
3.4. Final dataset for analysis
The full dataset with the properties listed in 2.3 consisted of 427
pairs of studies. Of these, 268 pairs of studies had no deaths at the
lower concentration, and it is this subset which is the subject of the
following analysis.
Fig. S1 shows the concentration ratios for the 268 pairs of
studies included in the ﬁnal dataset for analysis. The majority of
pairs had a concentration ratio in the range of >2 to 5 (80%), with
a large proportion of studies with a concentration ratio of >2 to 3
(39%). A smaller proportion of studies had concentration ratios of 5
or more (20%). Concentration ratios in excess of 10 were seen less
frequently (8%).
3.5. Most common signs excluding death at the lower concentration
There was a wide range of clinical signs recorded, relating to
behaviour, posture, appearance, secretions/excretions or respira-
tory related phenomena. The 20 most common signs, observed at
least once in at least one animal from day 1 onwards, are shown in
Table 6. Themost common signs have on thewhole higher values of
sensitivity, as expected, but can have very variable PPVs and
speciﬁcities. The effect of changing the number of animals experi-
encing a sign is shown in Table 7 for irregular respiration, for testsmals in the lower dose group where one animal has died, can increase the PPV. The
5% CI) Speciﬁcity (95% CI) No. studies No. animals
1.3e67.7) 100.0 (47.3e100.0) 29 132
1.5e33.2) 100.0 (47.3e100.0) 11 25
.7e28.9) 100.0 (47.3e100.0) 9 32
.0e24.4) 100.0 (47.3e100.0) 7 20
.8e22.1) 100.0 (47.3e100.0) 6 20
4.6e79.4) 50.0 (9.5e90.6) 38 121
9.5e65.9) 50.0 (9.5e90.6) 30 93
7.7e64.2) 50.0 (9.5e90.6) 29 87
Table 5
Effect of inclusion or exclusion of day 0 signs on PPV and speciﬁcity for irregular respiration (IR) and hypoactivity (L).
Clinical sign Code PPV (95% CI) Sensitivity (95% CI) Speciﬁcity (95% CI)
Irregular respiration IR Including day 0 86.3 (78.3e92.2) 39.6 (33.2e46.4) 78.7 (67.1e87.6)
Excluding day 0 89.0 (80.9e94.5) 35.3 (29.0e42.0) 85.2 (74.7e92.5)
Hypoactivity L Including day 0 92.3 (85.4e96.6) 40.6 (34.1e47.4) 88.5 (78.7e94.8)
Excluding day 0 100.0 (92.4e100.0) 18.4 (13.6e24.1) 100.0 (95.2e100.0)
Table 6
The 20 most common signs, observed at least once in at least one animal from day 1
onwards. The table also shows the number of animals showing the sign at least once.
Clinical sign Code No. animals
1 Irregular respiration IR 325
2 Noisy respiration RN 278
3 Hunched posture H 237
4 Respiration increased RI 169
5 Bodyweight loss BW 163
6 Laboured respiration RL 160
7 Piloerection P 116
8 Faeces reduced FR 107
9 Body staining ST 99
10 Naso-ocular discharge ND 91
11 Hypoactivity L 87
12 Congested respiration RC 87
13 Facial staining FAS 56
14 Ano-genital staining UGS 51
15 Appetite reduced AR 33
16 Gasping RG 30
17 Unkempt UG 25
18 Tremors T 15
19 Repetitive movements RM 10
20 Distended abdomen DA 8
F. Sewell et al. / Regulatory Toxicology and Pharmacology 73 (2015) 770e779776in which both 5 males and 5 females were included. PPV and
speciﬁcity are largely unchanged, but sensitivity decreases as the
requirement to see the sign in a higher and higher proportion of the
animals becomes increasingly unlikely. Similar conclusions were
reached for other common signs examined, i.e. small changes to
PPV and speciﬁcity and a loss of sensitivity. Therefore subsequent
analyses and recommendations are based on observation of the
sign at least once in at least one animal.
3.6. Clinical signs as predictors of toxicity at next highest
concentration
Since toxicity occurred at the higher concentration in 77% of the
studies where there were no deaths at the lower concentration, the
determination of evident toxicity (as opposed to death as an
endpoint) is only potentially useful if its predictive power (PPV) is
greater than this value (77%) and comparable to that of the obser-
vation of 1 death in a group of 5 animals (93%). There were a
number of individual signs whose PPVs were greater than 77% and
a smaller number whose PPVs were comparable to that of 1 death
and for which the lower 95% conﬁdence limits also exceeded 77%
(Table 8). Thesewere hypoactivity (L), tremors (T), bodyweight loss
(BW) and irregular respiration (IR). Tremors were not commonly
observed (low sensitivity) and therefore the contribution of this
sign is small.Table 7
The effect of changing the number of animals experiencing clinical sign irregular respira
No. animals with sign IR PPV (95% CI) Sensitivity
1 89.0 (80.9e94.5) 35.3
2 87.5 (78.3e93.7) 30.4
3 86.4 (76.5e93.1) 27.5
4 84.5 (73.5e92.1) 23.7
5 85.1 (72.8e93.2) 19.33.7. Body weight loss
In view of the possible value of body weight loss as an objective
marker of evident toxicity, we examined whether further reﬁne-
ment could be achieved by consideration of the extent of loss. In the
lexicon of signs, there were a number of sub-categories whose
numbers were pooled in the analysis of Table 8. These were: EM
(thin appearance, 252 observations), BW (extent not speciﬁed,1201
observations), BW (mild) (reduced weight gain, 182 observations),
BW (moderate) (loss 10e20%, 941 observations), BW (substantial)
(loss >20%, 144 observations). Where losses are quantiﬁed, these
are percentage lost compared to the pre-dosing weight on day 0. As
shown in Table 9, there is little to be gained from use of these sub-
categories as any modest improvement in PPV is at the expense of
wider conﬁdence limits and much reduced sensitivity.3.8. Combinations and co-occurrence of signs
Test data were examined for the presence of combinations of
signs i.e. one animal or more with either of sign A or sign B at the
lower exposure. All possible combinations of 2 signs were consid-
ered but the gains in sensitivity were small because of the strong
co-occurrence of signs i.e. signs are not truly independent of each
other. Similarly, inclusion of a third or fourth sign had progressively
lesser impact on any parameter.
The presence of any one of the three most highly predictive
signs (hypoactivity, bodyweight loss and irregular respiration) in at
least one animal had a PPV of nearly 91%, predicting 52% (sensi-
tivity) of the toxicity that occurred at the higher concentrationwith
only a 9% false positive rate (Table 10), which compares favourably
with the false positive rate of a single death at the lower concen-
tration. Addition of further signs in the same manner predicted a
larger proportion of the toxicity at the higher concentration, but
inevitably at the expense of a greater false positive rate.3.9. The effect of varying concentration ratios
The interval between the high and the low concentration in the
draft FCP guideline varies between two- and ten-fold. It was to be
expected that the larger the concentration ratio the more likely it
would be that toxicity would be found at the higher concentration
and conversely that a small concentration ratio would be associated
with greater risk of false positives. This was examined for the
common signs by comparing, for each sign in Table 11, the average
concentration ratio where false positive predictions were made
with the average concentration ratio for true positive predictions.tion (IR) on predictivity (PPV).
(95% CI) Speciﬁcity (95% CI) No. studies
(29.0e42.0) 85.2 (74.7e92.5) 82
(24.5e36.9) 85.2 (74.7e92.5) 72
(21.8e33.9) 85.2 (74.7e92.5) 66
(18.3e29.8) 85.2 (74.7e92.5) 58
14.4e25.1) 88.5 (78.7e94.8) 47
Table 8
The highly predictive signs in the absence of death (PPV above 73%). Signs observed at least once in at least one animal, excluding day 0.
Clinical sign Code PPV (95% CI) Sensitivity (95% CI) Speciﬁcity (95% CI) No. studies
Hypoactivity L 100.0 (92.4e100.0) 18.4 (13.6e24.1) 100.0 (95.2e100.0) 38
Tremors T 100.0 (68.8e100.0) 3.9 (1.9e7.2) 100.0 (95.2e100.0) 8
Bodyweight loss BW 94.0 (84.6e98.4) 22.7 (17.4e28.8) 95.1 (87.2e98.7) 50
Irregular respiration IR 89.0 (80.9e94.5) 35.3 (29.0e42.0) 85.2 (74.7e92.5) 82
Body staining ST 88.5 (71.8e97.0) 11.1 (7.4e15.9) 95.1 (87.2e98.7) 26
Ano-genital staining UGS 86.4 (67.3e96.4) 9.2 (5.8e13.7) 95.1 (87.2e98.7) 22
Faeces reduced FR 85.3 (70.4e94.4) 14.0 (9.8e19.2) 91.8 (82.8e96.9) 34
Naso-ocular discharge ND 85.0 (71.4e93.7) 16.4 (11.9e21.9) 90.2 (80.7e95.9) 40
Noisy respiration RN 81.2 (71.9e88.4) 33.3 (27.2e40.0) 73.8 (61.7e83.6) 85
Hunched posture H 78.8 (66.3e88.3) 19.8 (14.8e25.6) 82.0 (70.9e90.1) 52
Table 9
Effect of sub-categories of bodyweight loss on PPV. Sign observed at least once in at least one animal.
Clinical sign Code PPV (95% CI) Sensitivity (95% CI) Speciﬁcity (95% CI) No. studies
Bodyweight loss (unspeciﬁed) BW (unspeciﬁed) 100.0 (77.9e100.0) 5.8 (3.2e9.6) 100.0 (95.2e100.0) 12
Bodyweight loss (mild)a BW (mild) 100.0 (36.8e100.0) 1.4 (0.4e3.9) 100.0 (3.9e95.2) 3
Bodyweight loss (moderate)b BW (moderate) 94.4 (82.9e99.0) 16.4 (11.9e21.9) 96.7 (21.9e89.6) 36
Bodyweight loss (substantial)c BW (substantial) 100.0 (22.4e100.0) 1.0 (0.2e3.1) 100.0 (3.1e95.2) 2
Thin Thin 50.0 (2.5e97.5) 0.5 (0.1e2.3) 98.4 (2.3e92.2) 2
a Reduced weight gain.
b Weight loss 10e20% compared to pre-dosing weight on day 0.
c Weight loss >20% compared to pre-dosing weight on day 0.
Table 10
Combinations of highly predictive signs. PPV, sensitivity and speciﬁcity of studies where any one of the following signs are seen in any animal at least once, excluding day 0:
bodyweight loss (BW), hypoactivity (L) and/or irregular respiration (IR).
Combination of clinical signs Codes PPV (95% CI) Sensitivity (95% CI) Speciﬁcity (95% CI) No. studies
Hypoactivity, bodyweight loss and/or irregular respiration L, BW and/or IR 90.7 (84.4e95.0) 51.7 (44.9e58.4) 82.0 (70.9e90.1) 118
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frequently associated with smaller concentration ratios, an argu-
ment for a more rational experimental design. However, for the
four signs of highest PPV (hypoactivity, tremors, bodyweight loss
and irregular respiration), the ﬁrst two (hypoactivity and tremors)
are never associated with false positives, while for the second two
(bodyweight loss and irregular respiration), there was no signiﬁ-
cant effect of concentration ratio.
3.10. Sex differences
Some signs were more prevalent in one sex than the other.
Among the more common signs, ano-genital staining (UGS) was
more prevalent in females (p ¼ 0.0002) while facial staining (FAS)Table 11
Concentration ratios (the ratio between the lower and higher dose) and PPVs for commonl
those studies giving rise to false positive prediction of toxicity were compared with the a
The p-value is calculated from a t-test of whether the mean concentration ratio differs b
Clinical sign Code PPV (95% CI) Con
Fal
tox
Hypoactivity L 100.0 (92.4e100.0) e
Tremors T 100.0 (68.8e100.0) e
Bodyweight loss BW 94.0 (84.6e98.4) 4.9
Irregular respiration IR 89.0 (80.9e94.5) 4.3
Body staining ST 88.5 (71.8e97.0) 2.0
Ano-genital staining UGS 86.4 (67.3e96.4) 4.7
Faeces reduced FR 85.3 (70.4e94.4) 2.0
Naso-ocular discharge ND 85.0 (71.4e93.7) 3.4
Noisy respiration RN 81.2 (71.9e88.4) 3.6
Hunched posture H 78.8 (66.3e88.3) 2.5and gasping (RG) were marginally more common in males
(p ¼ 0.028 and 0.044, respectively). However, the predictivity of
these signs did not differ between males and females even for UGS
because of the wide conﬁdence limits particularly for the sex with
fewer observations where sensitivity was reduced.
4. Discussion of results
There are advantages and disadvantages of using archived data
for analyses of this type. The advantage is the gathering of a large
data set from which robust conclusions can be drawn. The disad-
vantage is that there is no way to control for laboratory-speciﬁc
differences in the nomenclature and recording of clinical signs.
We have tried to correct for this by creating a list of clinical signsy observed clinical signs. For each of the signs shown, average concentration ratios in
verage concentration ratios in those studies giving rise to true prediction of toxicity.
etween false and true positives.
centration ratios p-value
se positive (sign present but
icity does not occur)
True positive (sign present
& toxicity occurs)
4.09 e
4.56 e
7 3.57 0.610
0 5.14 0.296
6 3.61 0.001
1 3.50 0.671
7 3.89 <0.001
0 4.27 0.184
2 3.90 0.597
5 3.57 0.011
Table 12
Guidance on the recognition of evident toxicity.
Guidance on the recognition of evident toxicity
Evident toxicity has been reached if one or more animals display any one of the
listed signs (from day one onwards):
Clinical sign Code
Hypoactivity L
Tremors T
Bodyweight loss (>10%) BW
Irregular respiration IR
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the whole data set. Even so, there was some ambiguity and varia-
tion in detail in the responses that were provided (such as in-
dications of severity) and some judgement had to be applied in the
interests of harmonisation. Where any reclassiﬁcation was pro-
posed, this was always agreed with the originating organisation.
In the dataset that had no deaths at the lower concentration, and
regardless of what clinical signs were noted, toxicity occurred in
77% of the studies at the next higher concentration. Therefore, the
use of clinical signs other than death to deﬁne evident toxicity
clearly has to have a PPV greater than this to have any potential
value. What lower limit of the PPV above 77% is acceptable is
determined by attitudes to false positive rates, and in this there is
likely to be some diversity of opinion between safety, commercial
and 3Rs perspectives. The other benchmark of utility is compara-
bility with the predictive value of a single death at the lower con-
centration (PPV 93%), since this had already been proposed as a
criterion for GHS classiﬁcation in the draft OECD guideline. We
consider therefore several levels of the utility of clinical signs for
determining evident toxicity. Firstly there are signs whose PPVs are
comparable to that of a single death, whose lower 95% conﬁdence
limits exceed 77%, and for which speciﬁcity is high and sensitivity is
appreciable. These are L (hypoactivity), BW (body weight loss) and
IR (irregular respiration). These three signs satisfy the need to avoid
false positives, and are quite commonly observed resulting in
appreciable sensitivity. Body weight loss has previously been
shown to be a reliable objectivemarker for the determination of the
maximum tolerated dose (MTD) in short term toxicity tests in an-
imals to inform pharmaceutical development of potential candi-
date drugs (Chapman et al., 2013). Secondly, the presence of T
(tremors) also satisﬁes the need to avoid false positives but it is less
commonly observed with a sensitivity of only 3.8%. We propose
that the observation of any of these four signs indicates evident
toxicity. Thirdly, there is a further group of signswith PPVs in excess
of 77%, but with lower values of the lower 95% conﬁdence limit,
whose utility is further compromised in some instances by lower
speciﬁcity and limited sensitivity. It is therefore a matter of debate
whether the presence of these signs would be accepted as evident
toxicity.
In view of the complications inherent in using historical data, it
would be ideal to collect a prospective dataset in which the clinical
signs to be monitored had been agreed in advance, and include
additional information on severity in order to strengthen the case
for including the third category of signs as indicators of evident
toxicity.
A few signs showed differences in prevalence between males
and females. Earlier work had shown that in the case that males are
more sensitive than females, the FCP performs less well, and for
that reason a sighting study in both sexes was proposed (Stallard
et al., 2011). The present data do not alter this conclusion, since
the choice of sex only determines the frequency of certain signs not
their predictive value.
5. Recommendations and conclusions
5.1. Revised FCP protocol
Since we aim to encourage the adoption and acceptance of the
FCP by making the decision of evident toxicity more objective and
transparent wewant to ensure our recommendations are as simple
and effective as possible. Concentration fold change, severity,
timing, onset and duration of signs, the number of animals dis-
playing a sign were all considered and analysed for their ability to
predict toxicity at the next highest dose. However, it was found that
these analyses could be simpliﬁed to give a few highly predictivesigns that could indicate evident toxicity if observed at least once,
in one animal after the day of exposure.
If one ormore of the signs shown in Table 12 (T, L, BWand IR) are
observed in one or more animals during an acute inhalation study
there is no need to conduct a further study at a higher concentra-
tion, since this demonstrates that evident toxicity has been reached
and testing at a higher concentration will likely result in death or
severe suffering. Please note, we recommended that a limit of 10%
body weight is used, since this was the lowest quantiﬁable limit in
the dataset, and body weight loss in excess of 10% (from pre-dosing
weight on day 0) was shown to be highly predictive of toxicity at
the next highest concentration.
Therefore the recommendations for the FCP protocol are as
follows:
▪ A sighting study using one male and one female rat at each
concentration should be undertaken and subsequent testing
conducted in the more sensitive sex, or in females if no differ-
ence in sensitivity between sexes is observed (Stallard et al.,
2011).
▪ If 2 or more deaths occur in the main study, substance classiﬁ-
cation can be made or further testing should be carried out at
the concentration level below that tested, depending on the
starting concentration or previous concentrations tested (Fig. 3,
Outcome A).
▪ If there is 1 death or there is evident toxicity, classiﬁcation can
be made according to Table 1, irrespective of the starting con-
centration or previous concentrations tested (Fig. 3, Outcome B).
Evident toxicity has been reached if sign T, L, BW or IR is seen at
least once in at least one animal from day 1. However, these
recommendations are not intended to overrule study director
experience and judgement. If severe toxicity is observed on the
day of exposure or through the presentation of other signs not
listed here, the study should be stopped and animals euthanized
as appropriate.
▪ If there are no deaths and evident toxicity is not observed, non-
classiﬁcation can be concluded or further testing should be
carried out at the concentration level above that tested,
depending on the starting concentration or previous concen-
trations tested (Fig. 3, Outcome C).5.2. Next steps and conclusions
Adoption of the FCP in preference to the currently accepted
methods will reﬁne acute inhalation studies through the use of
evident toxicity rather than death as an endpoint. In addition, since
the FCP uses fewer animals than currently acceptedmethods, it also
has the potential to reduce the number of rats used in acute
inhalation toxicology studies worldwide.
With all three areas of concern now addressed: (i) compara-
bility; (ii) potential for sex differences; and (iii) the recognition of
evident toxicity, the working group will now seek international
F. Sewell et al. / Regulatory Toxicology and Pharmacology 73 (2015) 770e779 779acceptance of the FCP through adoption of OECD TG433 and
encourage its worldwide use in preference to other methods.
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